Market Newsdesk

Elastic Announces New Capabilities to Accelerate Threat Hunting Workflows, Prevent Ransomware, and Eliminate Blind Spots in Elastic Security

Arming Practitioners With Analyst-Driven Correlation, Behavioral Ransomware Prevention, and Nearly Unlimited Data Lookback Capabilities

• Accelerating threat hunting and investigation workflows with analyst-driven correlation powered by Event Query Language (EQL).
• Adding a new layer of ransomware prevention with behavioral analysis in the Elastic Agent.
• Leaving cyber threats nowhere to hide by making more data available to security analysts through schema on read, searchable snapshots, and enhanced search.

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Elastic (NYSE: ESTC) (“Elastic”), the company behind Elasticsearch and the Elastic Stack, recently announced new updates across the Elastic Security solution in the 7.12 release to accelerate threat hunting and investigation workflows, prevent ransomware, and eliminate blind spots. Enhanced capabilities include analyst-driven correlation, behavioral ransomware prevention, and unmatched data lookback with schema on read, searchable snapshots, and cross-cluster search.

Elastic Security streamlines security operation workflows and helps practitioners maximize data insights with analyst-driven correlation. Driven by Event Query Language (EQL) — the technology behind advanced correlation in the Elastic Security detection engine — analyst-driven correlation provides more targeted threat hunting and investigation with higher-fidelity detections derived from the findings that analysts uncover during those investigations. Security teams benefit from multiple detection and investigative methods that cover a broad range of security use cases. Combining EQL-based correlations with machine learning-based detections, indicator match type detection rules, and third-party context at cloud scale enables a more comprehensive security strategy.

Behavioral analysis with the Elastic Agent was also introduced to add a new layer of ransomware prevention in Elastic Security. Complementing the signatureless anti-malware first introduced in Elastic Security 7.9, behavioral ransomware prevention on the Elastic Agent detects and stops ransomware attacks on Windows systems by analyzing data from low-level system processes. It is effective across an array of widespread ransomware families, including those targeting the system’s master boot record.

Elastic Security is also expanding its data integrations and making it simple to migrate data from existing Splunk Enterprise environments with a connector that makes specific data sources available for rapid analysis, and added support for Cisco Advanced Malware Protection to analyze valuable endpoint data within Elastic Security. The Elastic Agent now collects several data sources that previously required Filebeat, including Sophos XG, Microsoft Defender ATP, and Google Cloud.

For more information read the Elastic blog about what’s new in Elastic Security 7.12.

About Elastic:

Elastic is a search company built on a free and open heritage. Anyone can use Elastic products and solutions to get started quickly and frictionlessly. Elastic offers three solutions for enterprise search, observability, and security, built on one technology stack that can be deployed anywhere. From finding documents to monitoring infrastructure to hunting for threats, Elastic makes data usable in real time and at scale. Thousands of organizations worldwide, including Cisco, eBay, Goldman Sachs, Microsoft, The Mayo Clinic, NASA, The New York Times, Wikipedia, and Verizon, use Elastic to power mission-critical systems. Founded in 2012, Elastic is a distributed company with Elasticians around the globe and is publicly traded on the NYSE under the symbol ESTC. Learn more at elastic.co.

The release and timing of any features or functionality described in this document remain at Elastic’s sole discretion. Any features or functionality not currently available may not be delivered on time or at all.

Elastic and associated marks are trademarks or registered trademarks of Elastic N.V. and its subsidiaries. All other company and product names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005812/en/

Elastic Public Relations

Ariel Roop

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Internet

MEDIA:

Logo

Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

− European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure

− Takeda Intends to Submit Regulatory Filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand During 2021

− TAK-003 is Being Studied for the Prevention of Dengue Due to any Dengue Virus Serotype in Individuals Ages Four to 60

OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited(TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the prevention of dengue due to any dengue virus serotype in individuals ages four to 60. Takeda intends to submit regulatory filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand during 2021.

“Submission of regulatory filings for our dengue vaccine candidate, TAK-003, marks an important development for people who are living in or traveling to communities burdened by the threat of dengue,” said Derek Wallace, VP, Dengue Global Program Leader at Takeda. “Dengue outbreaks, which result in half a million hospitalizations globally each year, can overwhelm communities and governments because of the broad impact on the health care system. With limited options to prevent the disease, there is a pressing need for widely available dengue vaccines. Takeda is committed to working with regulatory authorities and recommending bodies to support evaluation of our submissions and achieve access for TAK-003.”

Takeda is participating in the EMA’s first-ever parallel assessment of a medicinal product for use in the European Union (EU), and through the EU-M4all (previously Article 58) procedure for countries outside of the EU. Along with the scientific opinion issued by the Committee for Medicinal Products for Human Use (CHMP), national regulators in countries participating in the EU-M4all procedure will conduct their own assessments to determine if national marketing authorizations for TAK-003 are granted. Takeda is also seeking approval of TAK-003 in dengue-endemic countries that are not participating in the EU-M4all procedure.

Regulatory submissions for TAK-003 include long-term safety and efficacy data through 36 months from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. Takeda intends to present and publish details of the 36-month data at a scientific meeting and in a peer-reviewed journal this year.

Takeda also intends to submit regulatory filings in the United States, followed by additional countries in Asia and Latin America.

EU-M4all¹

EU-M4all (or EU-Medicines for all) is a procedure designed to facilitate patient access to essential medicines or vaccines intended to prevent or treat diseases of major public health interest. Through the EU-M4all procedure (previously known as the Article 58 procedure), the EMA, in cooperation with the World Health Organization (WHO), can provide scientific opinion on medicines and vaccines for public health priority diseases that are intended for markets outside of the EU.

About TAK-003

Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses.² Clinical Phase 2 data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants, which persisted through 48 months after vaccination, and the vaccine was found to be generally safe and well tolerated.³ The^{pivotal Phase 3 TIDES trialmet its primary endpoint of overall vaccine efficacy (VE) against virologically confirmed dengue (VCD) at 12 months follow-up and all secondary endpoints at 18 months follow-upfor which there were a sufficient number of dengue cases, including VE against hospitalized dengue and VE in baseline seropositive and baseline seronegative individuals.4,5 Efficacy varied by serotype. The results demonstrated TAK-003 was generally well tolerated, and there have been no important safety risks observed to date.}

About the Phase 3 TIDES (DEN-301) Trial

The double-blind, randomized, placebo-controlled Phase 3 TIDES trial is evaluating the safety and efficacy of two doses of TAK-003 in the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents.⁴ The TIDES trial is Takeda’s largest interventional clinical trial to date and enrolled over 20,000 healthy children and adolescents ages four to 16 years living in dengue-endemic areas. Study participants were randomly assigned to receive either TAK-003 0.5 mL or placebo by subcutaneous injection on Day 1 and Day 90.⁴ The study is comprised of five parts. Part 1 and the primary endpoint analysis evaluated vaccine efficacy (VE) and safety through 15 months after the first dose (12 months after the second dose).⁴ Part 2 continued for an additional six months to complete the assessment of the secondary endpoints of VE by serotype, baseline serostatus and disease severity, including VE against hospitalized dengue.⁴ Part 3 is evaluating VE and long-term safety by following participants for an additional two and a half to three years.⁶ Part 4 will evaluate safety for 13 months following booster vaccination and Part 5 will evaluate long-term safety for one year after completion of Part 4.⁶

The trial is taking place at sites in dengue-endemic areas in Latin America (Brazil, Colombia, Panama, the Dominican Republic and Nicaragua) and Asia (Philippines, Thailand and Sri Lanka) where there are unmet needs in dengue prevention and where severe dengue is a leading cause of serious illness and death among children.⁴ Baseline blood samples were collected from all individuals participating in the trial to allow for evaluation of safety and efficacy based on serostatus. Takeda and an independent Data Monitoring Committee of experts are actively monitoring safety on an ongoing basis.

About Dengue

Dengue is the fastest spreading mosquito-borne viral disease and was one of the WHO’s top 10 threats to global health in 2019.^7,8 Dengue is mainly spread by Aedes aegypti mosquitoes and, to a lesser extent, Aedes albopictus mosquitoes. It is caused by any of four dengue virus serotypes, each of which can cause dengue fever or severe dengue. The prevalence of individual serotypes varies across different geographies, countries, regions, seasons and over time.⁹ Recovery from infection by one serotype provides lifelong immunity against only that serotype, and later exposure to any of the remaining serotypes is associated with an increased risk of severe disease.

Dengue is pandemic prone, and outbreaks are observed in tropical and sub-tropical areas and have recently caused outbreaks in parts of the continental United States and Europe.^10,11 Approximately half of the world now lives under the threat of dengue, which is estimated to cause 390 million infections and around 20,000 deaths globally each year.^10,12 The dengue virus can infect people of all ages and is a leading cause of serious illness among children in some countries in Latin America and Asia.¹⁰

Takeda’s Commitment to Vaccines

Vaccines prevent 2 to 3 million deaths each year and have transformed global public health.¹³ For the past 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, COVID-19, Zika and norovirus. Takeda’s team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs. For more information, visit www.TakedaVaccines.com.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/ reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

###

---

¹The European Medicines Agency. Medicines for use outside the EU — EU-M4all. July 2020. Retrieved March 2021.

² Huang CY-H, et al. Genetic and phenotypic characterization of manufacturing seeds for tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. 2013;7:e2243.

³Tricou, V, Sáez-Llorens X, et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet. 2020. doi:10.1016/S0140-6736(20)30556-0.

⁴ Biswal S, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019; 2019;381:2009-2019.

⁵ Biswal S, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomized, placebo controlled, phase 3 trial. Lancet. 2020. 2020;395:1423-1433.

⁶ ClinicalTrials.Gov. Efficacy, Safety and Immunogenicity of Takeda’s Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES). Retrieved March 2021.

⁷ World Health Organization. Factsheet. Dengue and Severe Dengue. April 2019. Retrieved February 2021.

⁸ World Health Organization. Ten threats to global health in 2019. 2019. Retrieved February 2021.

⁹ Guzman MG, et al. Dengue: a continuing global threat. Nature Reviews Microbiology. 2010;8:S7-S16.

¹⁰ Knowlton K, et al. Mosquito-Borne Dengue Fever Threat Spreading in the Americas. The Natural Resources Defense Council (NRDC). 2009. Retrieved February 2021.

¹¹ Chan E, et al. Using web search query data to monitor dengue epidemics: a new model for neglected tropical disease surveillance. PLoS Negl Trop Dis. 2011;5:e1206.

¹² Centers for Disease Control and Prevention. About Dengue: What You Need to Know. May 2019. Retrieved February 2021.

¹³ UNICEF. Vaccination and Immunization Statistics. 2019. Retrieved February 2021.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005752/en/

Japanese Media

Kazumi Kobayashi

[email protected]

+81 (0) 3-3278-2095

Media Outside Japan

Rachel Wiese

[email protected]

+1 917-796-8703

KEYWORDS: Massachusetts North America United States Asia Pacific Japan Jamaica

INDUSTRY KEYWORDS: Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials

MEDIA:

Logo

Humana Inc. to Release First Quarter 2021 Results on April 28, 2021

LOUISVILLE, Ky.–(BUSINESS WIRE)–
Humana Inc. (NYSE: HUM) will release its financial results for the first quarter 2021 (1Q21) on Wednesday, April 28, 2021 at 6:30 a.m. Eastern time. The company will host a conference call at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2021.

All interested parties are invited to dial 888-625-7430. No password is required. A webcast of the 1Q21 earnings call may also be accessed via Humana’s Investor Relations page at www.humana.com. The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call.

For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at www.humana.com, approximately two hours following the live webcast. Telephone replays will be available from approximately 12:15 p.m. Eastern time on April 28, 2021 until 10:59 p.m. Eastern time on June 26, 2021 and can be accessed by dialing 855-859-2056 and providing the conference ID #9581139.

The company’s 1Q21 earnings news release is expected to include financial measures that are not in accordance with Generally Accepted Accounting Principles (GAAP). A reconciliation of non-GAAP financial measures to financial results under GAAP, as well as management’s reasons for including non-GAAP financial measures, will be included in the company’s 1Q21 earnings news release, a copy of which will be available on the Investor Relations page of www.humana.com on April 28, 2021.

About Humana

Humana Inc. (NYSE: HUM) is committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well-being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large.

To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools – such as in-home care, behavioral health, pharmacy services, data analytics and wellness solutions – combine to produce a simplified experience that makes health care easier to navigate and more effective.

More information regarding Humana is available to investors via the Investor Relations page of the company’s website at humana.com, including copies of:

• Annual reports to stockholders
• Securities and Exchange Commission filings
• Most recent investor conference presentations
• Quarterly earnings news releases and conference calls
• Calendar of events
• Corporate Governance information

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005721/en/

Amy Smith

Humana Investor Relations

(502) 580-2811

e-mail: [email protected]

Kelley Murphy

Humana Corporate Communications

(502) 224-1755

e-mail: [email protected]

KEYWORDS: Kentucky United States North America

INDUSTRY KEYWORDS: General Health Professional Services Health Insurance

MEDIA:

Posted on March 25, 2021 4:16 pm

Sun Life releases its 2020 Sustainability Report, outlines achievements and commitments to sustainability

PR Newswire

Highlights include over $60 billion invested in assets and businesses that support the transition to a low-carbon and more inclusive economy

TORONTO, March 25, 2021 /PRNewswire/ – Sun Life Financial Inc. (“Sun Life”) (TSX: SLF) (NYSE: SLF) today published its 2020 Sustainability Report and its 2020 Public Accountability Statement. The report highlights the organization’s progress and commitment to sustainability focusing on three key areas: sustainable investing, financial security and healthier lives. It also reports on topics related to operating as a trusted and responsible business: diversity, equity and inclusion, data security and privacy, governance and ethics. Sun Life issued the results of its sustainability performance and initiatives, demonstrating its ongoing commitment to sustainability in areas where they have the most positive impact on society and the environment.

“As a global leader, Sun Life plays a critical role in driving positive change. We’re committed not only to advancing our sustainability objectives but also championing and contributing to sustainability within our respective industries and in the business communities where we operate,” said Melissa Kennedy, Executive Vice-President, Chief Legal Officer and Public Affairs and Executive Sponsor of Sustainability, Sun Life. “Our approach to sustainability is integrated into our strategic priorities and purpose and builds on our foundation as a trusted and responsible business.”

2020 marked a year of extraordinary global events, all of which impacted societal health, equity, the environment and economies around the world. These events heightened and highlighted the importance of sustainability. Sun Life’s 2020 Sustainability Report shows many actions and outcomes where the company has helped its Clients around the world overcome the health and economic impacts of 2020.

“For Sun Life, sustainability means more than simply being accountable. It is about taking actions that drive social outcomes for our Clients, employees and communities over the long term,” added Kennedy.

Selected highlights from Sun Life’s 2020 Sustainability Report:

Advancing sustainable investing

• Reached over $60 billion in sustainable investments across its general account and third party investments (as at December 31, 2020). These assets and businesses contribute to a low-carbon and more inclusive economy, and meet criteria based on market standards.
• Broadened SLC Management’s alternative investment solutions for institutional Clients to include infrastructure equity and advance sustainable investment options through the majority acquisition of InfraRed Capital Partners.
• Introduced a new Environmental, Social and Governance (ESG) evaluation framework that helps Clients make informed decisions for sustainable investing through Sun Life’s Canadian Group Retirement Services business.

Increasing financial security

• Helped Clients in Canada take 1.2 million positive financial actions. For example, thanks to Sun Life’s digital coach, Ella, Clients placed $700 million in savings products and obtained $1 billion of insurance coverage.
• Grew the availability of products and services to help Clients in Asia increase their financial security. Launched new digital solutions across the region and partnered with two new bank distribution networks in Vietnam to make it easier for millions of Clients to get the coverage and advice they need.
• Expanded low-cost insurance options for consumers in the Philippines and Indonesia through strategic partnerships with MediCard and LinkAja, contributing to nearly 120,000 microinsurance policies issued to date.

Fostering healthier lives

• Launched Lumino Health Virtual Care in Canada, which connects Clients with medical practitioners for virtual consults. This offering helps Clients in need of enhanced medical support while social distancing.
• Helped U.S. Clients enrol easily in the benefit choices they needed through Sun Life’s Maxwell Health digital platform.
• Expanded their commitment to mental health through programs and services to help Clients and employees during challenging times.

Trusted and responsible business

• Intensified their goal to reach gender parity globally and to have 25 per cent under-represented communities with specific goals for Black, Indigenous and People of Colour in senior management roles in North America by 2025.
• Built a sustainability assessment process into all aspects of their corporate real estate operations in North America. Sun Life incorporates sustainability considerations in every step of a building’s lifecycle.
• Supports the Task Force on Climate-related Financial Disclosures (TCFD), and disclosed climate risks in line with the TCFD recommendations in its 2020 Annual Management Discussion and Analysis and the 2020 Annual Report.

Earlier in March, Sun Life announced its sustainable investing and climate change actions, including an investment commitment of C$20 billion in sustainable investments over the next five years across its General Account and third party investments. These additional investments may range from renewable energy, energy efficiency, sustainable buildings, clean transportation, water management, and social infrastructure projects such as hospitals. 

Sustainability is a key strategic priority for Sun Life. The 2020 Sustainability Report is the 10^th report issued and demonstrates its ongoing journey on its sustainability strategy. Since 2014, Sun Life has used the Global Reporting Initiative (GRI) framework to guide its reporting. This report is developed in accordance with the GRI Standards Core Option and reports on relevant disclosure topics identified in the Insurance and Asset Management standards developed by the Sustainability Accounting Standards Board (SASB).

Further details on Sun Life’s 2020 Sustainability Report and its 2020 Public Accountability Statement are available at sunlife.com/sustainability.

About Sun Life’s Sustainability Plan

Sun Life’s Sustainability Plan builds from a foundation as a trusted and responsible business. At its core is a focus on the areas where Sun Life can make the most positive social and environmental impact: increasing financial security, fostering healthier lives and advancing sustainable investing. Sun Life’s Sustainability Plan also focuses on minimizing its environmental footprint, supporting diversity, equity and inclusion in the workplace, data security and privacy, governance and ethics and risk management. In 2019, Sun Life also became the first life insurance company in the world to issue a sustainability bond. To learn more about Sun Life’s Sustainability Plan visit www.sunlife.com/en/sustainability/. 

About Sun Life 

Sun Life is a leading international financial services organization providing insurance, wealth and asset management solutions to individual and corporate Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of December 31, 2020, Sun Life had total assets under management of $1,247 billion. For more information please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Note to editors: All figures in Canadian dollars

Media Relations Contact: 
Abigail Bueno
Manager, Corporate Communications
416-802-8107
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/sun-life-releases-its-2020-sustainability-report-outlines-achievements-and-commitments-to-sustainability-301256375.html

SOURCE Sun Life Financial Inc.

Posted on March 25, 2021 4:15 pm

Cannae Holdings, Inc. Announces Foley Trasimene Acquisition Corp. II Stockholder Approval of Proposed Combination with Paysafe

Cannae Holdings, Inc. Announces Foley Trasimene Acquisition Corp. II Stockholder Approval of Proposed Combination with Paysafe

LAS VEGAS–(BUSINESS WIRE)–
Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae”) today announced that stockholders of Foley Trasimene Acquisition Corp. II (NYSE: BFT, BFT WS) (“Foley Trasimene”), a special purpose acquisition company, at the special meeting of Foley Trasimene stockholders (the “Special Meeting”) held today, voted in favor of the proposed business combination (the “Business Combination”) with Paysafe Group Holdings Limited (“Paysafe”). The completion of the Business Combination is expected to occur on Tuesday, March 30, 2021, subject to the satisfaction or waiver of customary closing conditions. Following the completion of the Business Combination, the newly combined company will operate as Paysafe and trade on the New York Stock Exchange (NYSE) under the symbol “PSFE” and is expected to start trading on Wednesday, March 31.

About Cannae Holdings, Inc.

Cannae Holdings, Inc. (NYSE: CNNE) is engaged in actively managing and operating a group of companies and investments, as well as making additional majority and minority equity portfolio investments in businesses, in order to achieve superior financial performance and maximize the value of these assets. Cannae was founded and is led by investor William P. Foley, II. Foley is responsible for the creation and growth of over $140 Billion in publicly traded companies including Fidelity National Information Services (“FIS”), Fidelity National Financial (“FNF”), and Black Knight, Inc. (“BKI”). Cannae’s current principal holdings include Dun & Bradstreet Holdings, Inc. (“DNB”), which recently completed a successful business transformation and IPO. Cannae holds an approximately 18% interest in Dun & Bradstreet or ~76 Million shares. Cannae’s second principal holding is Ceridian (“CDAY”), which Foley transformed from a legacy payroll bureau into a leading cloud-based provider of human capital management software. Cannae owns 9.5% of Ceridian representing approximately 14 Million shares.

About Foley Trasimene Acquisition Corp. II

Foley Trasimene Acquisition Corp. II is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. For more information, please visit www.foleytrasimene2.com.

About Paysafe

Paysafe Group (Paysafe) is a leading specialized payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through industry-leading capabilities in payment processing, digital wallet, and online cash solutions. With over 20 years of online payment experience, an annualized transactional volume of US $92 billion in 2020, and approximately 3,400 employees located in 12+ global locations, Paysafe connects businesses and consumers across 70 payment types in over 40 currencies around the world. Delivered through an integrated platform, Paysafe solutions are geared toward mobile-initiated transactions, real-time analytics and the convergence between brick-and-mortar and online payments. Further information is available at www.paysafe.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve a number of risks and uncertainties. Statements that are not historical facts, including statements regarding our expectations, hopes, intentions or strategies regarding the future are forward-looking statements. Forward-looking statements are based on management’s beliefs, as well as assumptions made by, and information currently available to, management. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The risks and uncertainties which forward-looking statements are subject to include, but are not limited to: changes in general economic, business and political conditions, including changes in the financial markets; our potential inability to find suitable acquisition candidates, acquisitions in lines of business that will not necessarily be limited to our traditional areas of focus, or difficulties in integrating acquisitions; significant competition that our operating subsidiaries face; compliance with extensive government regulation of our operating subsidiaries; risks associated with our split-off from Fidelity National Financial, Inc., including limitations on our strategic and operating flexibility related to the tax-free nature of the split-off and the Investment Company Act of 1940 and Investment Advisers Act, as well as the risk and uncertainties related to the success of our externalization.

This press release should be read in conjunction with the risks detailed in the “Statement Regarding Forward-Looking Information,” “Risk Factors” and other sections of our Quarterly Reports on Form 10-Q, Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005843/en/

Jamie Lillis, Managing Director, Solebury Trout, 203-428-3223, [email protected]

Shannon Devine, Senior Vice President, Solebury Trout, 203-428-3228, [email protected]

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Consulting Banking Professional Services Finance

MEDIA:

Posted on March 25, 2021 4:14 pm

IIROC Trading Resumption – PCLO.WT

Canada NewsWire

VANCOUVER, BC, March 25, 2021 /CNW/ – Trading resumes in:

Company: Pharmacielo Ltd.

TSX-Venture Symbol: PCLO.WT

All Issues: No

Resumption (ET): 9:30 AM3/26/2021

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Posted on March 25, 2021 4:14 pm

Arbor Realty Trust Announces Public Offering of Common Stock

UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (the “Company”) (NYSE: ABR) announced today that it plans to make a public offering of 7,000,000 shares of its common stock. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock.

The Company intends to use the net proceeds from the offering to make investments relating to its business and for general corporate purposes. The Company also intends to use a portion of the net proceeds from this offering to purchase (i) 350,000 shares of its common stock from its Chief Executive Officer, Arbor Commercial Mortgage, LLC and/or estate planning family vehicles established by its Chief Executive Officer (or 402,500 shares of its common stock if the underwriters exercise their option to purchase additional shares in full), (ii) 150,000 shares of its common stock from its Chief Financial Officer, (iii) 100,000 shares of its common stock from its Executive Vice President, Treasury and Servicing and (iv) 200,000 shares of its common stock from its Executive Vice President, Structured Securitization, at the same price the underwriters will purchase the shares in this offering.

J.P. Morgan, JMP Securities and Raymond James are joint book-running managers for the offering.

The offering will be made pursuant to an effective automatic shelf registration statement, previously filed by the Company with the Securities and Exchange Commission (“SEC”). The offering of these securities will be made only by means of a prospectus. Copies of the preliminary prospectus supplement and accompanying prospectus related to the offering may be obtained, when available, by contacting J.P. Morgan Securities LLC, Attention: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at [email protected]; JMP Securities LLC, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, Attention: Prospectus Department, or by calling (415) 835-8985, or by email at [email protected]; or Raymond James & Associates, Inc., Attention: Syndicate, 880 Carillon Parkway St. Petersburg, FL 33716, by telephone at (800) 248-8863, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Arbor Realty Trust, Inc.

Arbor Realty Trust, Inc. (NYSE: ABR) is a nationwide real estate investment trust and direct lender, providing loan origination and servicing for multifamily, seniors housing, healthcare and other diverse commercial real estate assets. Headquartered in New York, Arbor manages a multibillion-dollar servicing portfolio, specializing in government-sponsored enterprise products. Arbor is a Fannie Mae DUS® lender and Freddie Mac Optigo Seller/Servicer. Arbor’s product platform also includes CMBS, bridge, mezzanine and preferred equity lending.

Safe Harbor Statement

Certain items in this press release may constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the proposed offering and the anticipated use of the net proceeds from the offering. These statements are based on management’s current expectations and beliefs and are subject to a number of trends and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company can give no assurance that its expectations will be attained. Factors that could cause actual results to differ materially from the Company’s expectations include, but are not limited to, risks and uncertainties related to the completion of the offering on the anticipated terms or at all, market conditions, the satisfaction of customary closing conditions related to the offering, changes in economic conditions generally, and the real estate markets specifically, in particular, due to the uncertainties created by the COVID-19 pandemic, continued ability to source new investments, changes in interest rates and/or credit spreads, and other risks detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and its other reports filed with the SEC. Such forward-looking statements speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or change in events, conditions, or circumstances on which any such statement is based.

Contacts: Arbor Realty Trust, Inc. Paul Elenio, Chief Financial Officer 516-506-4422 [email protected]	Investors: The Ruth Group Daniel Kontoh-Boateng/James Salierno 646-536-7019/7028 [email protected] [email protected]